| Symbol | NCNA |
|---|---|
| Name | NUCANA PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3 LOCHSIDE WAY, EDINBURGH, EH12 9DT, United Kingdom |
| Telephone | +44 1313571111 |
| Fax | — |
| — | |
| Website | https://www.nucana.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001709626 |
| Description | NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States. Additional info from NASDAQ: |
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
Read moreBruce Theresa Margaret Ms 🟢 acquired 132.6M shares (1 derivative) of NuCana plc (NCNA) Transaction Date: Apr 15, 2026 | Filing ID: 159162
Read moreNew Form 3 - NuCana plc <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001193125-26-138044 <b>Size:</b> 25 KB
Read moreNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
Read moreNew Form 3 - NuCana plc <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116293 <b>Size:</b> 27 KB
Read moreNew Form S-8 - NuCana plc <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116227 <b>Size:</b> 354 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorecta… | Phase2 | Colorectal Cancer | Terminated | 2023-04-18 | 2024-08-29 | ClinicalTrials.gov |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumou… | Phase1 | Advanced Cancer | Terminated | 2023-03-08 | 2025-05-30 | ClinicalTrials.gov |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients Wit… | Phase3 | Biliary Tract Cancer | Terminated | 2019-12-24 | 2022-04-05 | ClinicalTrials.gov |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients W… | Phase1 | Advanced Cancer | Recruiting | 2019-06-17 | 2026-08-01 | ClinicalTrials.gov |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With St… | Phase1 | Colorectal Cancer | Completed | 2018-10-05 | 2024-03-21 | ClinicalTrials.gov |
| NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | Phase2 | Ovarian Cancer | Terminated | 2017-09-28 | 2019-12-31 | ClinicalTrials.gov |
| NCT01621854 | NUC-1031 in Patients With Advanced Solid Tumours | Phase1 | Cancer | Completed | 2012-10-01 | 2015-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NUC-1031 750mg | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT03146663 |
| NUC-1031 500 mg | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT03146663 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| NUC-1031 | Other | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| NUC-1031 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01621854 |
| NUC-3373 + bevacizumab | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI + EGFR inhibitor | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI + VEGF pathway inhibitor | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX + EGFR inhibitor | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX + VEGF pathway inhibitor | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUC-3373 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUC-3373 + leucovorin | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| Leucovorin | Other | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| Fosifloxuridine Nafalbenamide | Other | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| 5-FU | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Bevacizumab | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Leucovorin | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Fosifloxuridine Nafalbenamide | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT03829254 |
| NUC-7738 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT03829254 |
| Docetaxel | DRUG | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| 5-FU | DRUG | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Bevacizumab | BIOLOGICAL | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Irinotecan | DRUG | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT05678257 |
| Leucovorin | DRUG | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| Fosifloxuridine Nafalbenamide | DRUG | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| Cisplatin | DRUG | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| Gemcitabine | DRUG | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| NUC-1031 | DRUG | Phase PHASE3 | Biliary Tract Cancer | TERMINATED | NCT04163900 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Cancer | TERMINATED | NCT05714553 |
| NUC-7738 | DRUG | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT03829254 |
| NUC-3373 + bevacizumab | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI + EGFR inhibitor | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI + VEGF pathway inhibitor | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFIRI | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX + EGFR inhibitor | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX + VEGF pathway inhibitor | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUFOX | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUC-3373 | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUC-3373 + leucovorin | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT03428958 |
| NUC-1031 750mg | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT03146663 |
| NUC-1031 500 mg | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT03146663 |